Difference between revisions of "B72.3"

From Libre Pathology
Jump to navigation Jump to search
Line 18: Line 18:


==Use==
==Use==
===Negative===
*[[Mesothelioma]] - stains ~3% (6 of 196<ref name=pmid29048219/>).
===Positive===
===Positive===
*[[Mesothelioma]]
*Most carcinomas.<ref name=pmid1866206>{{Cite journal  | last1 = Betta | first1 = PG. | last2 = Pavesi | first2 = M. | last3 = Pastormerlo | first3 = M. | last4 = Tallarida | first4 = F. | last5 = Bellingeri | first5 = D. | last6 = Bocca | first6 = R. | title = Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions. | journal = Pathologica | volume = 83 | issue = 1083 | pages = 99-104 | month =  | year =  | doi =  | PMID = 1866206 }}</ref>
 
===Negative===
*Most carcinoma - stains ~3% (6 of 196<ref name=pmid29048219/>).


==See also==
==See also==

Revision as of 22:23, 22 January 2019

B72.3
Immunostain in short
Use mesothelioma versus carcinoma
Normal staining pattern cytoplasmic
Positive malignant mesothelioma
Negative most carcinomas

B72.3 in an immunostain useful in the diagnosis of malignant mesothelioma.[1]

Use

Negative

Positive

  • Most carcinomas.[2]

See also

References

  1. 1.0 1.1 Tandon, RT.; Jimenez-Cortez, Y.; Taub, R.; Borczuk, AC. (Feb 2018). "Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.". Arch Pathol Lab Med 142 (2): 236-242. doi:10.5858/arpa.2017-0092-OA. PMID 29048219.
  2. Betta, PG.; Pavesi, M.; Pastormerlo, M.; Tallarida, F.; Bellingeri, D.; Bocca, R.. "Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions.". Pathologica 83 (1083): 99-104. PMID 1866206.